Clinical trial
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With…
NCT00124579 · SWOG Cancer Research Network, Other · Terminated
Key facts
| NCT number | NCT00124579 |
|---|---|
| Title | S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | S0417 A Phase II Study of Bortezomib (Velcade™, PS-341), Thalidomide, and Dexamethasone in Patients With Refractory Multiple Myeloma |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | bortezomib, dexamethasone, thalidomide |
| Enrollment | 7 |
| Start date | Aug 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2010 |
| First posted | Jul 28, 2005 |
| Last update posted | Aug 9, 2018 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: